期刊文献+

贝那普利在2型糖尿病肾病患者中的应用及对其血清抵抗素水平的影响

Application of Benner Pury in Patients with Type 2 Diabetic Nephropathy and Its Influence on Serum Resistin Level
下载PDF
导出
摘要 目的探讨贝那普利在2型糖尿病肾病患者中的应用及对其血清抵抗素水平的影响。方法将随机抽取2013年10月—2014年10月在该院内分泌科治疗的100例2型糖尿病肾病患者随机分为两组,对照组采用常规治疗的方法,观察组在此基础上给予贝那普利治疗,比较两组患者的治疗效果、血糖水平、血清抵抗素水平、肾功能。结果观察组治疗有效率明显高于对照组,差异有统计学意义(P<0.05);观察组空腹血糖、餐后2h血糖、糖化血红蛋白明显较对照组改善,差异有统计学意义(P<0.05);观察组治疗后血清抵抗素水平明显低于对照组,差异有统计学意义(P<0.05);观察组BUN、Cr、24hUA明显较对照组改善,差异有统计学意义(P<0.05)。结论贝那普利在2型糖尿病肾病患者的治疗中效果显著,可降低血清抵抗素水平,改善病情进程。 Objective To study application of benner pury in patients with type 2 diabetic nephropathy and its influence on serum resistin level. Methods 100 patients with type 2 diabetic nephropathy treated in the Department of Endocrinology in our hospital between October 2013 and October 2014 were randomly divided into two groups: patients in the control group were given conven-tional treatment based on which those in the observation group were given benner pury. The curative effect, blood glucose, serum resistin levels and renal function of the two groups were compared. Results The treatment efficient of the observation group was obviously higher than that of the control group, and the difference was statistically significant (P〈0.05);In the observation group, compared with those in the control group, fasting blood glucose, 2h postprandial blood glucose and glycosylated hemoglobin were improved obviously, and the differences were statistically significant (P〈0.05);Of the observation group, serum resistin level after treatment was significantly lower than that of the control group, and the difference was statistically significant (P〈0.05);Of the ob-servation group, BUN, Cr, 24 hUA were improved obviously than those of the control group, and the differences were statistically significant (P〈0.05). Conclusion The effect of benner pury in the treatment of patients with type 2 diabetic nephropathy is signif-icant, and it can decrease the serum resistin levels and improve disease process.
作者 陈建伟 余渊
出处 《中外医疗》 2015年第18期129-131,共3页 China & Foreign Medical Treatment
关键词 2型糖尿病肾病 贝那普利 血清抵抗素 Type 2 diabetic nephropathy Benner Pury Serum resistin
  • 相关文献

参考文献4

二级参考文献33

  • 1李新胜,张金成,王瑞英.血清C反应蛋白、白介素6和肿瘤坏死因子α与2型糖尿病肾病的关系[J].临床荟萃,2005,20(9):494-496. 被引量:31
  • 2Ozturk S, Sar F, Bengi-Bozkurt O, Kazancioglu R. Study of ACEI versus ARB in managing hypertensive overt diabetic nephropathy: long-term analysis [J]. Kidney Blood Press Res, 2009, 32 (4) : 268-275.
  • 3Heart Outcomes Prevention Evaluation study investigators. Effects of ramip ril on cardiovascular and microvascular outcomes in people with diabetesmellitus[J]. Lancet. 2000, 355: 253-259.
  • 4Sasso Fc, Carbonara O, Persico M, et al. Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetc patients independently of hypertension [J]. Diabetes Care, 2002, 25: 1909-1913.
  • 5Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes[J]. Nature, 2001, 409 (6818): 307-312.
  • 6Satoh H, Nguyen MT, Miles PD, et al. Adenovirus-mediated chronic "hyperresistinemia" leads to in vivo insulin resistance in normal rats[J].J Clin Invest, 2004, 114 (4): 224-231.
  • 7Daghri AN, Cherty R, Teman PG, et al. Serum resistin is associated with C-reactive protein and LDL cholesterol in type 2 diabetes and coronary artery disease in a Saudi population [J]. Cardiovasc Diabetol, 2005, 4: 10.
  • 8Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients [J]. Arterioscler Thromb Vasc Biol. 2003, 20 (6) : 1595-1599.
  • 9Navarro-Gonza lez JF, Jarque A, Muros M, et al. Tumor necrosis factor-alpha as a therapeutic target for diabetic nephropathy. Cytokine Growth Factor Rev ,2009,20 : 165.
  • 10陈灏珠.实用内科学.第12版北京:人民卫生出版社,2005:1015.

共引文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部